The Science of Glaucoma Management: From Translational Research to Next-Generation Clinical Practice bridges the gap between laboratory research and clinicians by bringing the latest promising research directly from researchers to clinicians long before they translate into clinical advances, and often before they are presented at conferences. Organized as a series of clinically relevant topics written by world-leading experts, this book summarizes the current state of laboratory and translational research and draws on the potential implications for day-to-day clinical practice. It offers new…mehr
The Science of Glaucoma Management: From Translational Research to Next-Generation Clinical Practice bridges the gap between laboratory research and clinicians by bringing the latest promising research directly from researchers to clinicians long before they translate into clinical advances, and often before they are presented at conferences. Organized as a series of clinically relevant topics written by world-leading experts, this book summarizes the current state of laboratory and translational research and draws on the potential implications for day-to-day clinical practice. It offers new insights and mind-opening statements through contributions from some of the most respected glaucoma research groups. The book allows glaucoma specialists to explore novel ways to refine and rethink their practice based on the latest discoveries in basic sciences and breakthrough technologies, and to gain a better understanding on how their specialty is evolving and how research may shape tomorrow's practice.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Part 1: Currently Accepted Glaucoma Practice 1. Pathophysiology 2. Epidemiology 3. Diagnosis and investigations 4. Follow-up 5. Treatments 6. Section Summary: Discussion on the major unmet needs of the specialty Part 2: Pathophysiology and investigation methods 7. Glaucoma epidemiology: the role of genetics and biomarkers 8. Considerations for an efficient screening programmes for glaucoma 9. Ocular perfusion in glaucoma and the role of arterial blood pressure 10. The role of circadian and extrinsic intraocular pressure fluctuations 11. Pseudo-exfoliative glaucoma: epidemiology, pathophysiology and their clinical impact 12. Retinal and optic nerve micro-perfusion and the role of OCT-A 13. Structural testing modalities: cicrumpapillary RNFL, BMO-MRW, macular RNFL or vessel density? 14. Statistical considerations on visual field testing: how frequent is frequent-enough? 15. Novelties in functional testing: the role of contrast sensitivity, electrophysiology and colour vision 16. Section Summary: Diagnosing the grey zone and follow-up considerations Part 3: Medical and laser therapies 17. Social and psychological aspects of treatment adherence 18. Topical medications and ocular surface 19. Novel pressure-lowering medications and research alternatives 20. Novel drug delivery methods 21. Matrix metalloproteinase 22. Medical lasers, basic principles and core differences 23. Physiological principles and effects of SLT; discussion over the LIGHT Trial 24. Prophylactic iridotomy in narrow angle glaucoma 25. Aqueous dynamics, glaucoma and corneal health (considerations for iridotomies) 26. Section Summary: Recommendations in treatment-naïve open-angle glaucoma, treatment escalation protocols, and patient-specific considerations Part 4: Surgical options 27. Anatomical, mechanical and physiological effect of cataract surgery in open and narrow angle glaucoma 28. Anatomical considerations on trabecular meshwork, Schlemm's canal and collecting channels 29. The role of ocular inflammation, fluid dynamics and bleb morphology in surgical outcomes (including long-term conjunctival sensitization with fibroblast, aqueous inflammatory markers, and effect of aqueous flow on bleb viability; and considerations on early/delayed surgery) 30. Aqueous angiography and targeted surgery 31. Minimally-invasive glaucoma surgery (MIGS) device design considerations 32. Novel approaches to aqueous drainage 33. Adjustable drainage devices: benefits and shortcomings 34. Implantable intraocular pressure sensors and telemedicine 35. Laser-assisted surgery 36. Considerations on glaucoma clinical trials 37. Section Summary: Surgical considerations: Finding the best patient-surgeon-procedure match Part 5: New technologies 38. Artificial intelligence and Big Data: technical considerations and clinical applications 39. Detection of apoptosing retinal cells (DARC) in glaucoma 40. Neuroprotection and neurostimulation 41. Clinical trials in neuroprotection: special considerations 42. Neuro-regeneration and stem-cell therapies 43. Gene therapy 44. Section Summary: Predicting the future of glaucoma practice
Part 1: Currently Accepted Glaucoma Practice 1. Pathophysiology 2. Epidemiology 3. Diagnosis and investigations 4. Follow-up 5. Treatments 6. Section Summary: Discussion on the major unmet needs of the specialty Part 2: Pathophysiology and investigation methods 7. Glaucoma epidemiology: the role of genetics and biomarkers 8. Considerations for an efficient screening programmes for glaucoma 9. Ocular perfusion in glaucoma and the role of arterial blood pressure 10. The role of circadian and extrinsic intraocular pressure fluctuations 11. Pseudo-exfoliative glaucoma: epidemiology, pathophysiology and their clinical impact 12. Retinal and optic nerve micro-perfusion and the role of OCT-A 13. Structural testing modalities: cicrumpapillary RNFL, BMO-MRW, macular RNFL or vessel density? 14. Statistical considerations on visual field testing: how frequent is frequent-enough? 15. Novelties in functional testing: the role of contrast sensitivity, electrophysiology and colour vision 16. Section Summary: Diagnosing the grey zone and follow-up considerations Part 3: Medical and laser therapies 17. Social and psychological aspects of treatment adherence 18. Topical medications and ocular surface 19. Novel pressure-lowering medications and research alternatives 20. Novel drug delivery methods 21. Matrix metalloproteinase 22. Medical lasers, basic principles and core differences 23. Physiological principles and effects of SLT; discussion over the LIGHT Trial 24. Prophylactic iridotomy in narrow angle glaucoma 25. Aqueous dynamics, glaucoma and corneal health (considerations for iridotomies) 26. Section Summary: Recommendations in treatment-naïve open-angle glaucoma, treatment escalation protocols, and patient-specific considerations Part 4: Surgical options 27. Anatomical, mechanical and physiological effect of cataract surgery in open and narrow angle glaucoma 28. Anatomical considerations on trabecular meshwork, Schlemm's canal and collecting channels 29. The role of ocular inflammation, fluid dynamics and bleb morphology in surgical outcomes (including long-term conjunctival sensitization with fibroblast, aqueous inflammatory markers, and effect of aqueous flow on bleb viability; and considerations on early/delayed surgery) 30. Aqueous angiography and targeted surgery 31. Minimally-invasive glaucoma surgery (MIGS) device design considerations 32. Novel approaches to aqueous drainage 33. Adjustable drainage devices: benefits and shortcomings 34. Implantable intraocular pressure sensors and telemedicine 35. Laser-assisted surgery 36. Considerations on glaucoma clinical trials 37. Section Summary: Surgical considerations: Finding the best patient-surgeon-procedure match Part 5: New technologies 38. Artificial intelligence and Big Data: technical considerations and clinical applications 39. Detection of apoptosing retinal cells (DARC) in glaucoma 40. Neuroprotection and neurostimulation 41. Clinical trials in neuroprotection: special considerations 42. Neuro-regeneration and stem-cell therapies 43. Gene therapy 44. Section Summary: Predicting the future of glaucoma practice
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
